CClinicalTrials.gg
Sign In
Not yet recruitingNCT06348966Updated Apr 5, 2024

Predictors of Hospital Readmission for Chronic Obstructive Pulmonary Disease Patients

An observational study in Hospital Radmission for COPD Patients, sponsored by Assiut University. Not yet recruiting. Open to participants aged 25 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-04-05.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
188
Ages
25 Years to 80 Years
Sex
All
01

Study summary

This study is aimed to determine the risk factors for hospital readmission within 6 months in COPD patients

Read the detailed description

This study is aimed to determine the risk factors for hospital readmission within 6 months in COPD patients and develop early warning model

02

Conditions studied

  • Hospital Radmission for COPD Patients
03

In context

Lung Diseases, Obstructive

2,592 studies on the registry are indexed under Lung Diseases, Obstructive; 198 are open to participants now.

This study's planned enrollment of 188 is above the median of 150 across 639 observational studies indexed under Lung Diseases, Obstructive.

Browse Lung Diseases, Obstructive studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

this study is a prospective hospital-based cohort study

Inclusion criteria

  • All COPD patients of both genders diagnosed by (GOLD) Guidelines (2024 Revision).
  • Cooprative patients who accept to participate in the current study .

Exclusion criteria

Exclusion Criteria:

  • patients with cognitive impairment ,and unable to answer needed questions.
  • patients with other lung diseases such as active pulmonary tuberculosis ,asthma ,bronchiactesis,and pulmonary embolism .
  • patients with incomplete clinical data .
  • Refused to participate in the current study .
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
188 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. assessment of potential predictors of readmission among COPD patients

    using CCI (charlson comorbidity index)

    Time frame: 6 months

Secondary outcomes

  1. development of early warning model for hospital readmission in COPD patients

    using CCI (charlson comorbidity index)

    Time frame: within 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Alqahtani JS, Aldabayan YS, Aldhahir AM, Al Rajeh AM, Mandal S, Hurst JR. Predictors of 30- and 90-Day COPD Exacerbation Readmission: A Prospective Cohort Study. Int J Chron Obstruct Pulmon Dis. 2021 Oct 7;16:2769-2781. doi: 10.2147/COPD.S328030. eCollection 2021. PubMed 34675502 ↗
  • Anbesse ZK, Mega TA, Tesfaye BT, Negera GZ. Early readmission and its predictors among patients treated for acute exacerbations of chronic obstructive respiratory disease in Ethiopia: A prospective cohort study. PLoS One. 2020 Oct 6;15(10):e0239665. doi: 10.1371/journal.pone.0239665. eCollection 2020. PubMed 33022006 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06348966
Lead sponsor
Assiut University
Responsible party
Rougina Girgis Kamel Boles (resident doctor, Assiut University) — Principal investigator
First posted
Apr 5, 2024
Start date
May 1, 2024 (estimated)
Primary completion
May 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Apr 5, 2024

Study contacts

Rougina Girgis
Contact
rouginagirgis4@gmail.com
01273476615
Entsar Hsanen
Contact
entsar.hsanen@aun.edu.eg
01019968106

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lung Diseases, Obstructive→

Other studies from this sponsor

Assiut University

Start the discussion